{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:19:09Z","timestamp":1790410749707,"version":"4.1.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,21]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Plague, caused by the bacterium Yersinia pestis, has killed millions in historic pandemics and continues to cause sporadic outbreaks. Numerous antimicrobials are considered effective for treating plague; however, well-defined information on the relative efficacy of various treatments is lacking. We conducted a systematic review of published data on antimicrobial treatment of plague reported in aggregate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched databases including Embase, Medline, CINAHL, Cochrane Library, and others for publications with terms related to plague and antimicrobials. Articles were included if they contained 1) a group of patients treated for plague, with outcomes reported by antimicrobial regimen, and 2) laboratory evidence of Y. pestis infection or an epidemiologic link to patients with laboratory evidence of Y. pestis. Case fatality rate by antimicrobial regimen was calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 5837 articles were identified; among these, 26 articles published between 1939 and 2008 met inclusion criteria. A total of 2631 cases of human plague reported within these articles were included. Among cases classified by primary clinical form of plague, 93.6% were bubonic, 5.9% pneumonic, and 0.5% septicemic with associated case fatalities of 14.2%, 31.1%, and 20.0%, respectively. Case fatality rate among patients who received monotherapy with tetracyclines, chloramphenicol, aminoglycosides, or sulfonamides was 1.3%, 1.4%, 7.5%, and 20.2%, respectively. Fluoroquinolones were only given as part of combination therapy. Penicillin was associated with a case fatality rate of 75%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Tetracyclines, chloramphenicol, and aminoglycosides were associated with the lowest case fatality rates of all antimicrobials used for treatment of plague. Additional research is needed to determine the efficacy of fluoroquinolones as monotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciz1230","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T20:08:58Z","timestamp":1577995738000},"page":"S11-S19","source":"Crossref","is-referenced-by-count":30,"title":["Treatment of Human Plague: A Systematic Review of Published Aggregate Data on Antimicrobial Efficacy, 1939\u20132019"],"prefix":"10.1093","volume":"70","author":[{"given":"Shana","family":"Godfred-Cato","sequence":"first","affiliation":[{"name":"Infant Outcomes Monitoring, Research and Prevention Branch, Division of Birth Defects and Infant Disorders, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine M","family":"Cooley","sequence":"first","affiliation":[{"name":"Synergy America, contracting agency for Bacterial Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Fleck-Derderian","sequence":"first","affiliation":[{"name":"Oak Ridge Institute for Science and Education CDC Fellowship Program, Fort Collins, Colorado, USA"},{"name":"Bacterial Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi A","family":"Becksted","sequence":"first","affiliation":[{"name":"Oak Ridge Institute for Science and Education CDC Fellowship Program, Fort Collins, Colorado, USA"},{"name":"Bacterial Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Russell","sequence":"first","affiliation":[{"name":"Oak Ridge Institute for Science and Education CDC Fellowship Program, Fort Collins, Colorado, USA"},{"name":"Emergency Preparedness and Response Branch, Division of Preparedness and Emerging Infections, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Meaney-Delman","sequence":"first","affiliation":[{"name":"Infant Outcomes Monitoring, Research and Prevention Branch, Division of Birth Defects and Infant Disorders, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S","family":"Mead","sequence":"first","affiliation":[{"name":"Bacterial Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A","family":"Nelson","sequence":"first","affiliation":[{"name":"Bacterial Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,21]]},"reference":[{"key":"2020052103181431700_CIT0001","first-page":"278","article-title":"International meeting on preventing and controlling plague: the old calamity still has a future","year":"2006","journal-title":"Wkly Epidemiol Rec"},{"key":"2020052103181431700_CIT0002","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1128\/JCM.00064-11","article-title":"Characterization of an F1 deletion mutant of Yersinia pestis CO92, pathogenic role of F1 antigen in bubonic and pneumonic plague, and evaluation of sensitivity and specificity of F1 antigen capture-based dipsticks","volume":"49","author":"Sha","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2020052103181431700_CIT0003","first-page":"89","article-title":"Plague around the world, 2010\u20132015","volume":"91","author":"Bertherat","year":"2016","journal-title":"Wkly Epidemiol Rec"},{"key":"2020052103181431700_CIT0004","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1128\/JCM.01519-17","article-title":"Plague: recognition, treatment, and prevention","volume":"56","author":"Yang","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2020052103181431700_CIT0005","volume-title":"Plague, disease outbreak news.","year":"2019"},{"key":"2020052103181431700_CIT0006","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1001\/jama.283.17.2281","article-title":"Plague as a biological weapon: medical and public health management","volume":"283","author":"Inglesby","year":"2000","journal-title":"JAMA"},{"key":"2020052103181431700_CIT0007","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1371\/journal.pmed.0050003","article-title":"Plague: past, present, and future","volume":"5","author":"Stenseth","year":"2008","journal-title":"PLoS Med"},{"key":"2020052103181431700_CIT0008","volume-title":"Select agents and toxins list"},{"key":"2020052103181431700_CIT0009","first-page":"1","article-title":"Plague manual: epidemiology, distribution, surveillance and control","volume":"2","author":"Dennis","year":"1999","journal-title":"Geneva, Switzerland: World Health Organization,"},{"key":"2020052103181431700_CIT0010","doi-asserted-by":"crossref","first-page":"918","DOI":"10.15585\/mmwr.mm6433a6","article-title":"Human plague: United States, 2015","volume":"64","author":"Kwit","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020052103181431700_CIT0011","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3201\/eid2101.140564","article-title":"Epidemiology of human plague in the United States, 1900\u20132012","volume":"21","author":"Kugeler","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2020052103181431700_CIT0012","volume-title":"Products approved for other bioterrorism emergencies"},{"key":"2020052103181431700_CIT0013","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2807\/esm.09.12.00501-en","article-title":"Bichat guidelines for the clinical management of plague and bioterrorism-related plague","volume":"9","author":"Bossi","year":"2004","journal-title":"Euro Surveill"},{"key":"2020052103181431700_CIT0014","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1086\/381545","article-title":"Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in New Mexico, 1985\u20131999","volume":"38","author":"Boulanger","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020052103181431700_CIT0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/infdis\/167.1.173","article-title":"Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring","volume":"167","author":"Bertino","year":"1993","journal-title":"J Infect Dis"},{"key":"2020052103181431700_CIT0016","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","article-title":"Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases","volume":"38","author":"Peloquin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020052103181431700_CIT0017","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1158\/0008-5472.CAN-07-6061","article-title":"Chloramphenicol induces abnormal differentiation and inhibits apoptosis in activated T cells","volume":"68","author":"Yuan","year":"2008","journal-title":"Cancer Res"},{"key":"2020052103181431700_CIT0018","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1136\/bmj.287.6403.1424","article-title":"Chloramphenicol toxicity in neonates: its incidence and prevention","volume":"287","author":"Mulhall","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2020052103181431700_CIT0019","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-4632.2004.02108.x","article-title":"Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity","volume":"43","author":"Sanchez","year":"2004","journal-title":"Int J Dermatol"},{"key":"2020052103181431700_CIT0020","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz1226","article-title":"Antimicrobial treatment of human plague: a systematic review of the literature on individual cases, 1937\u20132019","author":"Nelson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2020052103181431700_CIT0021","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1086\/500137","article-title":"Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania","volume":"42","author":"Mwengee","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020052103181431700_CIT0022","first-page":"637","article-title":"Treatment of bubonic plague with sulfonamides and antibiotics","volume":"9","author":"Sokhey","year":"1953","journal-title":"Bull World Health Organ"},{"key":"2020052103181431700_CIT0026","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"The PRISMA Group preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2020052103181431700_CIT0027","volume-title":"National Institute for Health Research. International prospective register of systematic reviews"},{"key":"2020052103181431700_CIT0028","volume-title":"Google translate"},{"key":"2020052103181431700_CIT0029","first-page":"43","volume-title":"Diagnosis and clinical manifestations. Plague manual: epidemiology, distribution, surveillance and control. Geneva, Switzerland: World Health Organization","author":"Poland","year":"1999"},{"key":"2020052103181431700_CIT0030","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/archinte.1992.00400180107017","article-title":"Plague: a clinical review of 27 cases","volume":"152","author":"Crook","year":"1992","journal-title":"Arch Intern Med"},{"key":"2020052103181431700_CIT0031","first-page":"55","volume-title":"Treatment of plague. Plague manual--epidemiology, distribution, surveillance and control","author":"Poland","year":"1999"},{"key":"2020052103181431700_CIT0032","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/IAI.00140-15","article-title":"Comparison of models for bubonic plague reveals unique pathogen adaptations to the dermis","volume":"83","author":"Gonzalez","year":"2015","journal-title":"Infect Immun"},{"key":"2020052103181431700_CIT0033","volume-title":"Criteria for assessing internal validity of individual studies","author":"Appendix","year":"2017"},{"key":"2020052103181431700_CIT0034","first-page":"111","article-title":"A report of 42 cases of epidemic fulminant human plague in Guangxi Province, China","volume":"18","author":"Haijian","year":"2002","journal-title":"Chinese Journal of Zoonoses"},{"key":"2020052103181431700_CIT0035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/000992287301200512","article-title":"Plague as seen in South Vietnamese children: a chronicle of observations and treatment under adverse conditions","volume":"12","author":"Burkle","year":"1973","journal-title":"Clin Pediatr (Phila)"},{"key":"2020052103181431700_CIT0036","first-page":"295","article-title":"Analyses of diagnosis and treatment of 14 cases with human pneumonic plague in Qinghai Provence","volume":"27","author":"Batai","year":"2008","journal-title":"Chin J Endemiol"},{"key":"2020052103181431700_CIT0037","volume-title":"Medical microbiology & immunology. 2nd ed. Norwalk: Appleton & Lange","author":"Levinson","year":"1992"},{"key":"2020052103181431700_CIT0038","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0035-9203(48)90538-0","article-title":"Plague controlled in Haifa by the use of DDT alone","volume":"41","author":"Pollock","year":"1948","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020052103181431700_CIT0039","first-page":"442","article-title":"Streptomycin in bubonic plague","volume":"67","author":"Chen","year":"1949","journal-title":"Chin Med J"},{"key":"2020052103181431700_CIT0040","first-page":"21","article-title":"An outbreak of plague in Nanded with particular reference to treatment with sulpha drugs and streptomycin: a report on 407 cases","volume":"87","author":"Rao","year":"1952","journal-title":"Ind Med Gaz"},{"key":"2020052103181431700_CIT0041","volume-title":"FDA approves new antibacterial treatment for plague","year":"2012"},{"key":"2020052103181431700_CIT0042","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fmicb.2017.00091","article-title":"Inhaled liposomal ciprofloxacin protects against a lethal infection in a murine model of pneumonic plague","volume":"8","author":"Hamblin","year":"2017","journal-title":"Front Microbiol"},{"key":"2020052103181431700_CIT0043","doi-asserted-by":"crossref","first-page":"e959","DOI":"10.1371\/journal.pntd.0000959","article-title":"Levofloxacin cures experimental pneumonic plague in African green monkeys","volume":"5","author":"Layton","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"2020052103181431700_CIT0044","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1128\/AAC.39.9.2153","article-title":"In vitro antimicrobial susceptibilities of strains of Yersinia pestis","volume":"39","author":"Smith","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2020052103181431700_CIT0045","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz1233","article-title":"The African green monkey model of pneumonic plague and FDA approval of antimicrobials under the animal rule","author":"Hewitt","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2020052103181431700_CIT0046","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/367570","article-title":"A case of plague successfully treated with ciprofloxacin and sympathetic blockade for treatment of gangrene","volume":"36","author":"Kuberski","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020052103181431700_CIT0047","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3201\/eid2303.161212","article-title":"Successful treatment of human plague with oral ciprofloxacin","volume":"23","author":"Apangu","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2020052103181431700_CIT0023","first-page":"31","article-title":"On the epidemiology and treatment of plague in Egypt. \u201cThe 1940 Epidemic.\u201d","author":"Kamal","year":"1941","journal-title":"J Egypt Public Health Assoc"},{"key":"2020052103181431700_CIT0024","first-page":"14","volume-title":"Plague. Congo Belge: Rapport Sur L\u2019Hygiene Publique Au Congo Belge Pendant L\u2019Annee","author":"Van Hoof","year":"1939"},{"key":"2020052103181431700_CIT0025","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/infdis\/133.5.493","article-title":"Yersinia pestis infection in Vietnam. II. Quantiative blood cultures and detection of endotoxin in the cerebrospinal fluid of patients with meningitis","volume":"133","author":"Butler","year":"1976","journal-title":"J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/Supplement_1\/S11\/33244075\/ciz1230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/Supplement_1\/S11\/33244075\/ciz1230.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T19:26:17Z","timestamp":1665343577000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/Supplement_1\/S11\/5841431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":47,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2020,5,21]]},"published-print":{"date-parts":[[2020,5,21]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz1230","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5,1]]},"published":{"date-parts":[[2020,5,1]]}}}